Abcam, ab259171, Human TACC1 knockout HEK-293T cell lysate

Size: 1Kit
TACC1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon3 and 8 bp deletion in exon3.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon3 and 8 bp deletion in exon3.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TACC1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TACC1 also known as Transforming Acidic Coiled-Coil-Containing Protein 1 is a significant protein with a molecular mass of approximately 80 kDa. This protein primarily interacts in the centrosome and spindle microtubules of cells. TACC1 is an important player in regulating microtubule dynamics during mitosis and is widely expressed in various tissues including the brain liver and testis. The protein structure contains coiled-coil domains important for its function in stabilization and organization of microtubules.
Biological function summary
TACC1 engages in processes that contribute to proper cell division and genomic stability. It forms part of a larger molecular complex that includes components like the ch-TOG partner assisting in anchoring and stabilizing microtubules important for mitotic spindle function. TACC1 indirectly affects the balance between cell proliferation and apoptosis showing its importance in maintaining healthy cell cycles. Its role in spindle formation ensures accurate segregation of chromosomes which is critical for preventing aneuploidies.
Pathways
TACC1 is involved in mitotic signaling and microtubule organization pathways. It interacts with Aurora A kinase an essential element of the mitotic entry pathway ensuring that kinetochores are properly attached to spindle microtubules during mitosis. Another pathway involves the PI3K/AKT signaling where TACC1 may influence cellular responses to growth factors. Its interaction with Aurora A demonstrates the protein's importance in centrosome maturation and spindle stability highlighting its role in cell cycle regulation.
TACC1 relates to certain cancers particularly breast and ovarian cancer. Aberrant expression or mutations of TACC1 can lead to disrupted cellular proliferation control and genomic instability. In breast cancer TACC1 often shows altered expression alongside BRCA1 suggesting a direct connection within pathways that govern tumor suppression and DNA repair. Ovarian cancer studies also indicate that changes in TACC1 levels could correlate with tumor aggressiveness positioning it as a potential prognostic marker.